Glaukos Corporation (6GJ)
XSTU 
Summary
6GJ Chart
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos Corporation (6GJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Glaukos Corporation ever had a stock split?
Glaukos Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Thomas William Burns CEO | XSTU Exchange | US3773221029 ISIN |
| US Country | 995 Employees | - Last Dividend | - Last Split | 25 Jun 2015 IPO Date |
Overview
Glaukos Corporation stands as a pioneering entity within the ophthalmic pharmaceutical and medical technology sector, dedicated to crafting innovative treatments for a spectrum of eye diseases. This includes glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and based in Aliso Viejo, California, the corporation not only embarks on research and development but also actively markets its breakthrough products globally. Their strategy encompasses both direct sales organizations within the United States and partnerships with distributors on an international scale, showcasing their commitment to addressing prevalent ocular conditions worldwide.
Products and Services
iStent and iStent inject W micro-bypass stents: Tailored for individuals undergoing cataract surgery, these innovative micro-bypass stents are engineered to enhance aqueous humor outflow. They specifically target mild-to-moderate open-angle glaucoma, aiming to alleviate intraocular pressure and mitigate the disease's progression. The iStent technology represents a significant advancement in glaucoma management, providing a minimally invasive solution to patients grappling with this chronic condition.
iStent Infinite: This device is designed for the treatment of glaucoma patients whose condition remains uncontrolled despite previous medical and surgical interventions. The iStent Infinite system underscores Glaukos Corporation's dedication to developing solutions for more severe stages of glaucoma, offering hope to those with limited treatment options. Its application in managing uncontrolled glaucoma demonstrates the company's innovative approach to tackling the complexities of this eye disease.
iDose TR: Featuring as an intracameral procedural pharmaceutical therapy, iDose TR is aimed at reducing intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. This product represents a cutting-edge development in glaucoma treatment, promising a novel, sustained delivery method for therapeutics directly into the eye. It exemplifies Glaukos Corporation's commitment to advancing glaucoma care through innovative drug delivery systems.
